Bausch Health Files 8-K on Operations and Financials
Ticker: BHC · Form: 8-K · Filed: Oct 30, 2024 · CIK: 885590
Sentiment: neutral
Topics: financial-reporting, operations, company-history
TL;DR
Bausch Health dropped an 8-K on Oct 30th - check their financials!
AI Summary
Bausch Health Companies Inc. filed an 8-K on October 30, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company was formerly known as Valeant Pharmaceuticals International, Inc. and BIOVAIL Corp.
Why It Matters
This filing provides investors with an update on Bausch Health's financial performance and operational status, which can influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine filing providing financial updates and does not indicate any immediate or significant risks.
Key Players & Entities
- Bausch Health Companies Inc. (company) — Registrant
- Valeant Pharmaceuticals International, Inc. (company) — Former Company Name
- BIOVAIL Corp (company) — Former Company Name
- October 30, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Bausch Health Companies Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was this 8-K filing submitted?
This 8-K filing was submitted on October 30, 2024.
What were some of Bausch Health Companies Inc.'s former names?
Bausch Health Companies Inc. was formerly known as Valeant Pharmaceuticals International, Inc. and BIOVAIL Corp.
Where is Bausch Health Companies Inc. headquartered?
Bausch Health Companies Inc.'s principal executive offices are located at 2150 St. Elzéar Blvd. West, Laval, Québec, Canada H7L 4A8.
What is the Standard Industrial Classification code for Bausch Health Companies Inc.?
The Standard Industrial Classification code for Bausch Health Companies Inc. is PHARMACEUTICAL PREPARATIONS [2834].
Filing Stats: 615 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-10-30 16:16:15
Filing Documents
- bhc-20241030.htm (8-K) — 30KB
- ex991-q3x2024.htm (EX-99.1) — 747KB
- image2a.jpg (GRAPHIC) — 8KB
- 0000885590-24-000034.txt ( ) — 956KB
- bhc-20241030.xsd (EX-101.SCH) — 2KB
- bhc-20241030_lab.xml (EX-101.LAB) — 22KB
- bhc-20241030_pre.xml (EX-101.PRE) — 13KB
- bhc-20241030_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On October 30, 2024, Bausch Health Companies Inc. (the "Company") issued a press release announcing results of operations for the quarter ended September 30, 2024 and certain other financial information as of and for the quarter ended September 30, 2024. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by this reference. This Current Report on Form 8-K and the press release attached hereto as Exhibit 99.1 do not constitute an offer to sell or the solicitation of an offer to buy any securities. The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended (the " Securities Act").
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1* Press Release of Bausch Health Companies Inc., respecting financial results for the third quarter of 2024 dated October 30, 2024 101.SCH* XBRL Taxonomy Extension Schema Document 101.LAB* XBRL Taxonomy Extension Label Linkbase Document 101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document 104* Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) ____________________________________ * Filed herewith.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 30, 2024 BAUSCH HEALTH COMPANIES INC. By: /s/ JEAN-JACQUES CHARHON Jean-Jacques Charhon Executive Vice President, Chief Financial Officer (Principal Financial Officer)